

26th March 2020

Dear colleague,

Bristol Myers Squibb Update (BMS)

The spread of coronavirus (COVID-19) and its implications can be worrying for many people living with a cancer diagnosis and their families. That is why we wanted to update you on Bristol Myers Squibb's response to the pandemic.

As the situation continues to evolve, Bristol Myers Squibb (BMS) is taking proactive steps to protect and support the health and well-being of the patients, people and communities we serve.

As we all navigate this challenge together, our highest priority remains our patients. We remain fully committed to delivering our medicines and services to patients in the most responsible way possible.

In line with Government guidance, we have moved to a remote working situation, until the end of April or as required. Many meetings and interactions are being replaced by virtual/digital interactions, where possible, and some of you have already experienced this approach in the last few weeks. These changes are intended to be temporary as we continue to monitor and assess the situation, and we will provide additional updates as we learn more.

We fully understand that many of you will be having to manage a high volume of enquiries from concerned patients and their families during this worrying time. Many of you will be aware of the specific guidance that has been shared by One Cancer Voice charities in partnership with NHS England (see attached), which may be a helpful reference.

Over the coming days, we will be considering ways in which we can enhance our support for patients and the charities which support them; if you have specific needs please do reach out to your usual contact points within the Policy Advocacy and Government Affairs team at Bristol Myers Squibb to share more details.

For now, we would like to thank you for all that you are doing to support people with cancer and their loved ones at this difficult time.

Regards,

Lynelle Hoch
General Manager, UK & Ireland
Bristol Myers Squibb

Faisal Mehmud
Head of Medical Affairs, UK & Ireland
Bristol Myers Squibb